There are currently 1572 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
NCT04660344
Recruiting
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Texas Oncology-Medical City Dallas, Dallas, Texas
Conditions: Muscle-invasive Bladder Cancer
Register for Updates
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of age).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
05/31/2024
Locations: Cedar Health Research, Dallas, Texas
Conditions: Acute Treatment of Migraine
Register for Updates
The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System
NCT04129125
Recruiting
The trial is designed to assess the safety and efficacy of using the Zoom Reperfusion System in subjects diagnosed with acute ischemic stroke and undergoing a thrombectomy procedure within 8 hours of last known well.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Baylor Scott and White Research Institute, Dallas, Texas
Conditions: Ischemic Stroke, Acute Stroke
Register for Updates
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
NCT05583526
Recruiting
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
Gender:
All
Ages:
12 years and above
Trial Updated:
05/31/2024
Locations: Modern Research Associates, PLLC, Dallas, Texas
Conditions: Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Register for Updates
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
NCT05813275
Recruiting
This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: FutureSearch Trials of Dallas, LP, Dallas, Texas
Conditions: OSA
Register for Updates
Dystonia Genotype-Phenotype Correlation
NCT03428009
Recruiting
The purpose of this study is to (1) investigate the effect of known dystonia-causing mutations on brain structure and function, to (2) identify structural brain changes that differ between clinical phenotypes of dystonia, and to (3) collect DNA, detailed family history, and clinical phenotypes from patients with idiopathic dystonia with the goal of identifying new dystonia-related genes. Investigators will be recruiting both healthy control subjects and subjects with any form of dystonia. For th... Read More
Gender:
All
Ages:
11 years and above
Trial Updated:
05/31/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Dystonia, Dystonia; Idiopathic, Dystonia, Primary, Dystonia, Secondary, Dystonia, Familial, Dystonia Disorder, Dystonias, Sporadic, Dystonia; Orofacial, Dystonia Lenticularis, Dystonia, Paroxysmal, Dystonia 6, Dystonia 5, Dystonia 8, Dystonia 9, Dystonia 19, Dystonia 10, Dystonia 11, Dystonia 20, Dystonia 12, Dystonia, Focal, Dystonia of Head, Dystonia, Diurnal
Register for Updates
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
NCT05121103
Recruiting
This study will include participants with relapsed/refractory (R/R) Multiple Myeloma (MM). MM is a type of cancer of the blood. This study will also include participants with relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). DLBCL is also a type of cancer of the blood. They are referred to as 'relapsed' when the disease has come back after treatment and 'refractory' when treatment no longer works. The study has 2 main parts, called phase 1 and phase 1b. The main objective of both... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Baylor University Medical Center (Texas Oncology), Dallas, Texas
Conditions: Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
Register for Updates
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
NCT05836987
Recruiting
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Gender:
All
Ages:
Between 22 years and 85 years
Trial Updated:
05/31/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Atrial Fibrillation
Register for Updates
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
NCT04241835
Recruiting
This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat. The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe hepatic (liver) impairment will be compared with participants with advanced malignancies and normal hepatic function. An advanced malignancy is a cancer that has recurred (come back) after prior treatment or hasn't controlled with treatment. The trial will also study th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Hepatic Impairment, Advanced Malignant Solid Tumor
Register for Updates
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
NCT05627362
Recruiting
This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease of the liver that leads to injury and destruction of bile ducts. Damage to bile ducts leads to buildup of bile in the liver, which then causes further damage, and leads to disease progression. This study will compare elafibranor to a placebo, a dummy treatment. The main objective of the trial will be to study the safety and side effects of the stud... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/31/2024
Locations: University Of Texas Southwestern Medical Center At Dallas, Dallas, Texas
Conditions: Primary Sclerosing Cholangitis
Register for Updates
AMX0035 and Progressive Supranuclear Palsy
NCT06122662
Recruiting
ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of a randomized double blind placebo controlled phase, followed by an optional open-label extension phase.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
05/31/2024
Locations: Kerwin Medical Center, Dallas, Texas
Conditions: Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
Register for Updates
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
NCT05011058
Recruiting
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas
Conditions: Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma, EBV-Positive DLBCL, Nos, EBV Associated Lymphoma, EBV Related PTCL, Nos
Register for Updates